Abstract
The sphingomyelin breakdown products sphingosine-1-phosphate (S1P) and sphingosylphosphorylcholine (SPC) constrict intrarenal microvessels in vitro in a pertussis toxin (PTX) sensitive manner, and S1P also reduces renal blood flow in vivo. Nevertheless, both S1P and SPC have been reported to enhance diuresis and natriuresis. This pattern is similar to that of neuropeptide Y, which also reduces renal blood flow and enhances diuresis and natriuresis. The latter effects are inhibited by the cyclooxygenase inhibitor indomethacin, and various S1P and SPC responses have also been linked to the cyclooxygenase pathway. Therefore, we have investigated whether indomethacin can alter the renal effects of S1P and SPC in anaesthetised rats in vivo. In line with earlier experiments S1P bolus injections dose-dependently reduced renal blood flow (by up to 4.8±0.5 ml min−1), and this was not significantly affected by indomethacin treatment (5 mg kg−1 i.p.). Infusion of S1P but not of SPC (30 μg kg−1 min−1 each) for 60 min reduced renal blood flow by up to 0.8±0.2 ml min−1, and this was not markedly altered by indomethacin. Despite the differential renovascular effect, both S1P and SPC enhanced diuresis by up to 215±65 and 201±58 μl 15 min−1 respectively, and natriuresis by up to 25±9 and 29±11 μmol 15 min−1 respectively. While indomethacin abolished the SPC-induced diuresis and natriuresis, it, if anything, slightly enhanced the diuretic and natriuretic effect of S1P. To determine whether tubular SPC effects are receptor-mediated, PTX experiments were performed. SPC-induced enhancements of diuresis and natriuresis were abolished by PTX. We conclude that S1P, SPC and neuropeptide Y exhibit distinct patterns of modulation of renal function and that indomethacin allows such effects to be differentiated.
Similar content being viewed by others
References
Alewijnse AE, Michel MC (2006) Sphingosine-1-phosphate and sphingosylphosphorylcholine—two of a kind? Br J Pharmacol http://dx.doi.org/10.1038/sj.bjp.0706602
Alewijnse AE, Peters SLM, Michel MC (2004) Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br J Pharmacol 143:666–684
Bernatchez PN, Tremblay F, Rollin S, Neagoe P-E, Sirois MG (2003) Sphingosine 1-phosphate effect on endothelial cell PAF synthesis: role in cellular migration. J Cell Biochem 90:719–731
Bischoff A, Michel MC (1998) Renal effects of neuropeptide Y. Pflügers Arch 435:443–453
Bischoff A, Erdbrügger W, Smits J, Michel MC (1996) Neuropeptide Y-enhanced diuresis and natriuresis in anaesthetized rats is independent from renal blood flow reduction. J Physiol (Lond) 495:525–534
Bischoff A, Avramidis P, Erdbrügger W, Münter K, Michel MC (1997) Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y. Br J Pharmacol 120:1335–1343
Bischoff A, Limmroth V, Michel MC (1998) Indomethacin inhibits the natriuretic effects of neuropeptide Y in anesthetized rats. J Pharmacol Exp Ther 286:704–708
Bischoff A, Czyborra P, Fetscher C, Meyer zu Heringdorf D, Jakobs KH, Michel MC (2000a) Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. Br J Pharmacol 130:1871–1877
Bischoff A, Czyborra P, Meyer zu Heringdorf D, Jakobs KH, Michel MC (2000b) Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br J Pharmacol 130:1878–1883
Bischoff A, Finger J, Michel MC (2001a) Nifedipine inhibits sphingosine-1-phosphate-induced renovascular contraction in vitro and in vivo. Naunyn-Schmiedebergs Arch Pharmacol 364:179–182
Bischoff A, Meyer zu Heringdorf D, Jakobs KH, Michel MC (2001b) Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetised rats. Br J Pharmacol 132:1925–1933
Chalfant CE, Spiegel S (2005) Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci 118:4605–4612
Chen PF, Chin TY, Chueh SH (1998) Ca2+ signaling induced by sphingosylphosphorylcholine and sphingosine 1-phosphate via distinct mechanisms in rat glomerular mesangial cells. Kidney Int 54:1470–1483
Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, Pyne S, Tigyi G (2002) International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54:265–269
Damirin A, Tomura H, Komachi M, Tobo M, Sato K, Mogi C, Nochi H, Tamoto K, Okajima F (2005) Sphingosine 1-phosphate receptors mediate the lipid-induced cAMP accumulation through cyclooxygenase-2/prostaglandin I2 pathway in human coronary artery smooth muscle cells. Mol Pharmacol 67:1177–1185
Dantas APV, Igarashi J, Michel T (2003) Sphingosine 1-phosphate and control of vascular tone. Am J Physiol 284:H2045–H2052
Davaille J, Gallois C, Habib A, Li L, Mallat A, Tao J, Levade T, Lotersztajn S (2000) Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway. J Biol Chem 275:34628–34633
Hedemann J, Fetscher C, Michel MC (2004) Comparison of noradrenaline and lysosphingolipid-induced vasoconstriction in mouse and rat small mesenteric arteries. Auton Autacoid Pharmacol 24:77–85
Lynch KR, Im D-S (1999) Life on the edg. Trends Pharmacol Sci 20:473–475
Mathieson FA, Nixon GF (2006) Sphingolipids differentially regulate mitogen-activated protein kinases and intracellular Ca2+ in vascular smooth muscle: effects on CREB activation. Br J Pharmacol http://dx.doi.org/10.1038/sj.bjp.0706600
Meyer zu Heringdorf D, Himmel HM, Jakobs KH (2002) Sphingosylphosphorylcholine—biological functions and mechanisms of action. Biochim Biophys Acta 1582:178–189
Nakamura H, Takashiro Y, Hirabayashi T, Horie S, Koide Y, Nishida A, Murayama T (2004) Effects of synthetic sphingosine-1-phosphate analogs on arachidonic acid metabolism and cell death. Biochem Pharmacol 68:2187–2196
Orlati S, Porcelli AM, Hrelia S, Lorenzini A, Rugolo M (1998) Intracellular calcium mobilization and phospholipid degradation in sphingosylphosphorylcholine-stimulated human airway epithelial cells. Biochem J 334:641–649
Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, Chalfant CE, Obeid LM, Hannun YA (2003) The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J 17:1411–1421
Pettus BJ, Kitatani K, Chalfant CE, Taha TA, Kawamori T, Bielawski J, Obeid LM, Hannun YA (2005) The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate. Mol Pharmacol 68:330–335
Spiegel S, Milstien S (2000) Functions of a new family of sphingosine-1-phosphate receptors. Biochim Biophys Acta 1484:107–116
Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4:397–407
Acknowledgement
This work has been supported in part by a grant of the Deutsche Forschungsgemeinschaft.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Czyborra, C., Bischoff, A. & Michel, M.C. Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine. Naunyn Schmied Arch Pharmacol 373, 37–44 (2006). https://doi.org/10.1007/s00210-006-0037-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-006-0037-6